CHRNA3

CHRNA3 encodes the α3 subunit of neuronal nicotinic acetylcholine receptors, an essential component of fast cholinergic neurotransmission in autonomic ganglia (PMID:33947782, PMID:11450844). Biallelic loss-of-function variants in humans cause familial autonomic ganglionopathy with diffuse panautonomic failure—severe neurogenic orthostatic hypotension, miosis, constipation, and low norepinephrine—with structural modeling placing the recurrent D230N missense variant at the subunit–subunit interface of the nAChR pentamer, predicting destabilized receptor assembly (PMID:33947782); the phenotypic spectrum extends to neurogenic bladder and gastrointestinal dysmotility (PMID:38192228). This autonomic role is corroborated by α3 knockout mice, which develop megacystis, bladder strips that fail to contract in response to nicotine, dilated pupils, and perinatal mortality (PMID:11450844). CHRNA3 lies in a gene cluster with CHRNA5 and CHRNB4 (PMID:9921897), and its expression is governed by cis-regulatory variants: rs2036527 sits in an enhancer that physically loops to the CHRNA3 promoter and binds FOXA2, controlling allele-specific expression of CHRNA3 and CHRNA5 (PMID:40755048), while intergenic SNPs confer allele-specific nuclear-protein and GATA factor binding that modulates reporter expression (PMID:23872218). Functionally, common CHRNA3 variants influence sensorimotor gating (prepulse inhibition) and its genotype-dependent modulation by nicotine (PMID:20393456, PMID:23604333), and in zebrafish chrna3 loss of function blunts the normal transition from alcohol attraction to aversion through altered glutamatergic, GABAergic, and cholinergic signaling (PMID:40992927).

1. 1998 Medium

   Establishing the intron-exon organization and chromosomal clustering of CHRNA3 provided the structural framework needed for systematic variant analysis and revealed its physical linkage to CHRNB4 and CHRNA5.

   Evidence genomic cloning, sequencing, and chromosomal mapping

   PMID:9921897

   Open questions at the time

   • Does not address receptor function or expression regulation
   • No link to phenotype established at this stage
2. 2001 Medium

   Knockout mouse phenotyping demonstrated that the α3 subunit is required for autonomic ganglionic neurotransmission, addressing whether CHRNA3 has an essential physiological role.

   Evidence α3 knockout mouse phenotyping (megacystis, nicotine-unresponsive bladder, mydriasis, perinatal lethality) referenced alongside human polymorphism analysis

   PMID:11450844

   Open questions at the time

   • Mouse phenotype cited rather than generated de novo here
   • No human disease variant yet identified
3. 2010 Medium

   Genetic association across two independent cohorts linked common CHRNA3 variants to prepulse inhibition, addressing whether α3-subunit variation affects a measurable neurophysiological function (sensorimotor gating).

   Evidence PPI association study in healthy volunteers and schizophrenia patients with combined p-value analysis

   PMID:20393456

   Open questions at the time

   • Association-based, no direct mechanistic link to receptor function
   • Causal variant not resolved within the LD block
4. 2011 Low

   Reporter and allelic-imbalance experiments tested whether cluster haplotypes drive expression differences, finding the CHRNA3 promoter itself largely unaffected while CHRNA5 was regulated, refining where regulatory effects act.

   Evidence luciferase reporter assay in neuroblastoma cells and allelic expression imbalance analysis in post-mortem brain

   PMID:21858091

   Open questions at the time

   • CHRNA3-specific result is largely negative
   • Single lab, no functional follow-up on identified elements
5. 2013 Medium

   EMSA and reporter assays identified allele-specific nuclear-protein and GATA factor binding at intergenic SNPs, addressing the molecular basis by which regulatory variants alter CHRNA3/B4 expression.

   Evidence luciferase reporter and EMSA with nuclear extracts in neuronal and lung cancer cell lines

   PMID:23872218

   Open questions at the time

   • In vitro binding not validated in vivo at the endogenous locus
   • Quantitative effect on receptor levels not measured
6. 2013 Medium

   A controlled pharmacological challenge showed that nicotine's effect on prepulse inhibition depends on CHRNA3 genotype, establishing a genotype × drug interaction at the level of sensorimotor gating.

   Evidence double-blind placebo-controlled within-subjects PPI study with genotyping and cotinine confirmation in nonsmokers

   PMID:23604333

   Open questions at the time

   • Mechanism linking genotype to nicotine response at the receptor not resolved
   • Single lab, modest sample size
7. 2020 Low

   Replicated association tied cluster variants to gastrointestinal adverse events during smoking-cessation pharmacotherapy, addressing whether the locus tags a drug-response pathway.

   Evidence logistic regression in a placebo-controlled cessation trial with independent-cohort replication

   PMID:30882151

   Open questions at the time

   • No molecular mechanism identified
   • Cannot attribute effect specifically to CHRNA3 within the cluster
8. 2021 Medium

   Whole-exome sequencing of two families established CHRNA3 loss of function as a cause of human panautonomic failure and modeled the D230N variant at the pentamer subunit interface, defining the disease mechanism as impaired receptor assembly.

   Evidence whole-exome sequencing, cosegregation in two families, structural modeling of D230N at the nAChR interface

   PMID:33947782

   Open questions at the time

   • No in vitro reconstitution confirming assembly destabilization
   • Functional consequence of frameshift alleles not directly assayed
9. 2024 Low

   A new compound heterozygous case extended the CHRNA3 disruption phenotype to include CAKUT with dysautonomia, broadening the clinical spectrum.

   Evidence clinical genetic sequencing and phenotyping of a single patient

   PMID:38192228

   Open questions at the time

   • Single patient, no functional validation of variants
   • Causality not established beyond co-occurrence
10. 2025 Medium

    Functional genomics identified rs2036527 as a cis-regulatory enhancer that loops to the CHRNA3 promoter and binds FOXA2, naming the transcription factor and physical mechanism controlling CHRNA3/CHRNA5 expression.

    Evidence chromosome conformation capture, luciferase enhancer assay, FOXA2 ChIP, and allele-specific expression analysis

    PMID:40755048

    Open questions at the time

    • FOXA2 dependence not tested by knockdown at the endogenous locus
    • Tissue specificity of the enhancer not fully delineated
11. 2025 Medium

    Zebrafish chrna3 loss-of-function established a causal requirement for the receptor in normal alcohol aversion, linking α3 to a behavioral phenotype with defined neurotransmitter-system correlates.

    Evidence two-choice self-administration assay in chrna3 mutants, behavioral phenotyping, and brain transcriptomics

    PMID:40992927

    Open questions at the time

    • Circuit-level mechanism connecting chrna3 to aversion not resolved
    • Zebrafish ortholog; generalization to mammals untested
12. 2026 Medium

    Using CHRNA3 as a marker, a subclass of mechanoinsensitive visceral nociceptors was shown to be sensitized in colitis via NGF-TrkA/pERK/PIEZO2 signaling, defining a sensory-neuron population relevant to visceral pain.

    Evidence rat colitis model with tracing, in situ hybridization, pERK blockade, chemogenetic silencing, and electrophysiology

    PMID:42157236

    Open questions at the time

    • CHRNA3 used as a cell-type marker; its receptor function not directly tested here
    • Rat model; relevance to human visceral pain not established

• Whether the disease-associated and behavior-associated CHRNA3 variants act by altering pentamer assembly, channel gating, or expression level remains to be directly demonstrated in a reconstituted receptor system.
• No functional reconstitution of human α3-containing receptors with disease variants
• Subunit composition of the physiologically relevant receptor not defined in the corpus